Tandem Diabetes Care Announces Pricing of $16.2 Million Underwritten Public Offering of Common Stock and Warrants
Business Wire 13-Oct-2017 9:10 AM
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of (i) 4,630,000 shares of its common stock, (ii) Series A warrants to purchase 4,630,000 shares of its common stock and (iii) Series B warrants to purchase 4,630,000 shares of its common stock, for gross proceeds of approximately $16.2 million, at a public offering price of $3.50 per share and accompanying warrants. The Series A warrants have an exercise price of $3.50 per share, are immediately exercisable and will expire on the fifth anniversary of the date of issuance. The Series B warrants have an exercise price of $3.50 per share, are immediately exercisable and will expire on the six-month anniversary of the date of issuance. The shares of common stock and the warrants will be immediately separable and will be issued separately. All of the shares of common stock and warrants to be sold in the offering are being offered by Tandem.
Tandem intends to use the net proceeds from the proposed offering for working capital and other general corporate purposes. The offering is expected to close on or about October 17, 2017, subject to customary closing conditions.
Oppenheimer & Co. Inc. is acting as the sole bookrunning manager for the offering. National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NasdaqCM: NHLD), is acting as a co-manager in connection with the offering.
This offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed by Tandem with theSecurities and Exchange Commissionand declared effective onDecember 19, 2014. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering has been filed with the Securities and Exchange Commission (SEC) and will form a part of the effective registration statement and a final prospectus supplement will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may be obtained from: Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8563 or by email atEquityProspectus@opco.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the Securities and Exchange Commissions website at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of a prospectus that forms a part of the registration statement.
About Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 Insulin Pump, the only pump capable of remote feature updates using a personal computer, now available with Dexcom G5 Mobile continuous glucose monitoring (CGM) integration, and the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom G5 is a registered trademark of Dexcom, Inc.
Forward Looking Statements This press release contains forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements.These forward-looking statements include statements regarding the closing of the public offering, the anticipated proceeds from the offering and other statements that are not purely statements of historical fact. Such forward-looking statements are based on the Companys current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results, and the timing of events, may differ materially from those indicated by such forward-looking statements due to numerous risks and uncertainties, including the Companys ability to satisfy closing conditions related to the proposed offering. Other risks and uncertainties are identified in the final prospectus supplement and accompanying prospectus relating to the proposed offering, the Companys most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission including the Registration Statement on Form S-3 (File No. 333-200686) for the offering. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Unless otherwise required by applicable law or the rules of the NASDAQ Stock Market, Tandem undertakes no obligation to update or revise any forward-looking statement in this press release because of new information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171013005150/en/
Tandem Diabetes Care, Inc. Media Contact:Steve Sabicer, email@example.comInvestor Contact:Susan Morrison, 858-366-6900 firstname.lastname@example.org
Source: Tandem Diabetes Care, Inc.